Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and Adverse Effects of Medications Used in the Treatment of Glaucoma

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

With the advent of several new topically active medications for glaucoma therapy, intraocular pressure (IOP) can be reduced to target levels in more patients before resorting to surgery. Some of these newer agents have a number of advantages over some of the older medications, several of which are seldom used now. The topically active carbonic anhydrase inhibitors are better tolerated than oral formulations, which are infrequently used despite their greater efficacy compared with the topical formulations. The α2-adrenergic agonists effectively reduce IOP with few systemic adverse effects. The prostaglandin analogues are even more effective and well tolerated when applied once daily without known systemic adverse effects.

The variety of glaucoma medications forces the physician to be selective with various combinations before proceeding with surgery. This article critically reviews the literature pertaining to the newer glaucoma medications, thereby providing guidelines to make rational choices from among the available options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox: a preliminary report. Am J Ophthalmol 1954; 37(1): 13–5

    PubMed  CAS  Google Scholar 

  2. Zimmerman TJ, Kaufman HE. Timolol: dose response and duration of action. Arch Ophthalmol 1977; 95(4): 605–7

    Article  PubMed  CAS  Google Scholar 

  3. Chacko DM, Camras CB. The potential of α2-adrenergic agonists in the medical treatment of glaucoma. Curr Opin Ophthalmol 1994; 5(2): 76–84

    Article  Google Scholar 

  4. Robin AL. Apraclonidine hydrochloride: its past, present, and future in the therapy of chronic glaucoma. J Glaucoma 1995; 4Suppl. 1: S24–9

    PubMed  Google Scholar 

  5. Robin AL, Ritch R, Shin DH, et al. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Am J Ophthalmol 1995; 120(4): 423–32

    PubMed  CAS  Google Scholar 

  6. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996; 41Suppl. 1: S27–37

    Article  PubMed  Google Scholar 

  7. Strahlman E, Tipping R, Vogel R, et al. A double-masked, randomized 1-year study comparing dorzolamide(trusopt),timolol, and betaxolol. Arch Ophthalmol 1995; 113(8): 1009–16

    Article  PubMed  CAS  Google Scholar 

  8. Silver LH, the Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1998; 126(3): 400–8

    Article  PubMed  CAS  Google Scholar 

  9. Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 1998; 105(10): 1945–51

    Article  PubMed  CAS  Google Scholar 

  10. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology 1995; 102(12): 1743–52

    PubMed  CAS  Google Scholar 

  11. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103(1): 138–47

    PubMed  CAS  Google Scholar 

  12. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103(1): 126–37

    PubMed  CAS  Google Scholar 

  13. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: a12 weekstudy. Arch Ophthalmol 1996; 114(8): 929–32

    Article  PubMed  CAS  Google Scholar 

  14. Alward WLM. Medical management of glaucoma. N Engl J Med 1998; 339(18): 1298–307

    Article  PubMed  CAS  Google Scholar 

  15. Sugrue MF. New approaches to antiglaucoma therapy. J Med Chem 1997; 40(18): 2793–809

    Article  PubMed  CAS  Google Scholar 

  16. Wayman L, Larsson L-I, Maus T, et al. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997; 115(11): 1368–71

    Article  PubMed  CAS  Google Scholar 

  17. Larsson L-I, Alm A. Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide. Arch Ophthalmol 1998; 116(1): 19–24

    PubMed  CAS  Google Scholar 

  18. Maus TL, Larsson L-I, McLaren JW, et al. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997; 115(1): 45–9

    Article  PubMed  CAS  Google Scholar 

  19. Rosenberg LF, Krupin T, Tang L-Q, et al. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology 1998; 105(1): 88–93

    Article  PubMed  CAS  Google Scholar 

  20. Strahlman E, Tipping R, Vogel R, et al. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol 1996; 122(2): 183–94

    PubMed  CAS  Google Scholar 

  21. LeBlanc RP, for the Brimonidine Study Group 2. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology 1998; 105(10): 1960–7

    Article  PubMed  CAS  Google Scholar 

  22. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. Arch Ophthalmol 1997; 115(7): 847–52

    Article  PubMed  CAS  Google Scholar 

  23. Camras CB, Wax MB, Ritch R, et al. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. Am J Ophthalmol 1998; 126(3): 390–9

    Article  PubMed  CAS  Google Scholar 

  24. Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 1998; 105(10): 1952–9

    Article  PubMed  CAS  Google Scholar 

  25. Adamsons I, Clineschmidt C, Polis A, et al. The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. J Glaucoma 1998; 7(4): 253–60

    Article  PubMed  CAS  Google Scholar 

  26. Strahlman ER, Vogel R, Tipping R, et al. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology 1996; 103(8): 1283–93

    PubMed  CAS  Google Scholar 

  27. Laibovitz R, Strahlman ER, Barber BL, et al. Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J Glaucoma 1995; 4(5): 306–13

    Article  PubMed  CAS  Google Scholar 

  28. Mehta NH, Simmons ST, Alphagan/Trusopt Study Group. The safety and efficacy of brimonidine and dorzolamide as concomitant therapy in primary open angle glaucoma and ocular hypertension [abstract]. Invest Ophthalmol Vis Sci 1998; 39(4): S481

    Google Scholar 

  29. Alm A, Widengård I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995; 79(1): 12–6

    Article  PubMed  CAS  Google Scholar 

  30. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2α analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994; 78(12): 899–902

    Article  PubMed  CAS  Google Scholar 

  31. Diestelhorst M, Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 1998; 236: 577–81

    Article  PubMed  CAS  Google Scholar 

  32. Emmerich KH. A comparison of latanoprost monotherapy to dorzolamide combined with timolol in glaucoma and ocular hypertension patients. American Academy of Ophthalmology Final Program; 1998 Nov 8–11; New Orleans, 137

  33. Ciappetta R, Frezzotti P, Nuti A et al. Additivity of latanoprost and pilocarpine to timolol in POAG patients [abstract]. Invest Ophthalmol Vis Sci 1998; 39(4): S256

    Google Scholar 

  34. Stewart R, the Brinzolamide Comfort Study Group. The ocular comfort of tid-dosed brinzolamide 1.0% compared to tiddosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension [abstract]. Invest Ophthalmol Vis Sci 1997; 38(4): S559

    Google Scholar 

  35. Lass JH, Khosrof SA, Laurence JH, et al. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Arch Ophthalmol 1998; 116(8): 1003–10

    PubMed  CAS  Google Scholar 

  36. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993; 111(10): 1343–50

    Article  PubMed  CAS  Google Scholar 

  37. Uva MG, Longo A, Ott JP, et al. 2% Dorzolamide and cornea: an ultrabiomicroscopic study [abstract]. Invest Ophthalmol Vis Sci 1998; 39(4): S708

    Google Scholar 

  38. Egan CA, Hodge DO, McLaren JW, et al. Effect of dorzolamide on corneal endothelial function in normal human eyes. Invest Ophthalmol Vis Sci 1998; 39(1): 23–9

    PubMed  CAS  Google Scholar 

  39. Konowal A, Morrison JC, Brown SVL, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999; 127: 403–6

    Article  PubMed  CAS  Google Scholar 

  40. Herndon LW, Choudhri SA, Cox T, et al. Central corneal thickness in normal, glaucomatous, and ocular hypertensive eyes. Arch Ophthalmol 1997; 115(9): 1137–41

    Article  PubMed  CAS  Google Scholar 

  41. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997; 115(9): 1206–8

    Article  PubMed  CAS  Google Scholar 

  42. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124(4): 544–7

    PubMed  CAS  Google Scholar 

  43. Watson PG, the Latanoprost Study Group. Latanoprost: two years’ experience of its use in the United Kingdom. Ophthalmology 1998; 105(1): 82–7

    Article  PubMed  CAS  Google Scholar 

  44. Albert DM, Green WR, Grossniklaus HE et al. Histopathological finding in iris specimens from patients with glaucoma treated with latanoprost. American Academy of Ophthalmology Final Program; 1998 Nov 8–11; New Orleans, 153

  45. Zhan G-L, Toris CB, Camras CB, et al. Prostaglandin-induced iris color darkening: an experimental model. Arch Ophthalmol 1998; 116(8): 1065–8

    PubMed  CAS  Google Scholar 

  46. Zhan G-L, Ohia SE, Camras CB, et al. Superior cervical ganglionectomy-induced lowering ofintraocular pressure in rabbits: role of prostaglandins and neuropeptide Y. Gen Pharmacol 1999; 32: 189–94

    Article  PubMed  CAS  Google Scholar 

  47. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol 1997; 124(5): 683–5

    PubMed  CAS  Google Scholar 

  48. Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol 1998; 116(5): 679–80

    PubMed  CAS  Google Scholar 

  49. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: experience and incidence in a retrospective review. Ophthalmology 1998; 105(2): 263–8

    Article  PubMed  CAS  Google Scholar 

  50. Gaddie IB, Bennett DW. Cystoid macular edema associated with the use of latanoprost. J Am Optom Assoc 1998; 69(2): 122–8

    PubMed  CAS  Google Scholar 

  51. Heier JS, Steinert RF, Frederick AR. Cystoid macular edema associated with latanoprostuse. Arch Ophthalmol 1998; 116(5): 680–2

    PubMed  CAS  Google Scholar 

  52. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol 1998; 126(1): 134–5

    Article  PubMed  CAS  Google Scholar 

  53. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 1998; 126(4): 602–4

    Article  PubMed  CAS  Google Scholar 

  54. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998; 126(1): 37–41

    Article  PubMed  CAS  Google Scholar 

  55. Camras CB. CME and anterior uveitis with latanoprost use [letter]. Ophthalmology 1998; 105(11): 1978–81

    Article  PubMed  CAS  Google Scholar 

  56. Schumer RA, Camras CB, Mandahl A. Occurrence of cystoid macular edema in eyes treated with latanoprost: preliminary analysis. In: Krieglstein GK, editor. Glaucoma update VI. Heidelberg: Springer-Verlag. In press

  57. Eisenberg DL. CME and anterior uveitis with latanoprost use [letter]. Ophthalmology 1998; 105(11): 1978–81

    Article  PubMed  CAS  Google Scholar 

  58. Thorne JE, Maguire AM, Lanciano R. CME and anterior uveitis with latanoprost use [letter]. Ophthalmology 1998; 105(11): 1981–3

    Article  PubMed  CAS  Google Scholar 

  59. Carlsen J, Durcan J, Zabriskie N, et al. Nephrolithiasis with dorzolamide. Arch Ophthalmol 1999; 117: 1087–8

    Article  PubMed  CAS  Google Scholar 

  60. Biollaz J, Munafo A, Buclin T, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol 1995; 47: 455–60

    Article  PubMed  CAS  Google Scholar 

  61. Hodapp E, Kolker AE, Kass MA, et al. The effect of topical clonidine on intraocular pressure. Arch Ophthalmol 1981; 99(7): 1208–11

    Article  PubMed  CAS  Google Scholar 

  62. Coleman AL, Robin AL, Pollack IP, et al. Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine. Arch Ophthalmol 1990; 108(9): 1264–7

    Article  PubMed  CAS  Google Scholar 

  63. Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of0.2%brimonidine. Arch Ophthalmol 1995; 113(1): 77–83

    Article  PubMed  CAS  Google Scholar 

  64. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate:a one-month dose response study. Ophthalmology 1997; 104(1): 131–6

    PubMed  CAS  Google Scholar 

  65. Carlsen JO, Zabriskie NA, Kwon YH, et al. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol 1999; 128: 255–6

    Article  PubMed  CAS  Google Scholar 

  66. Stjernschantz J, Selén G, Sjöquist B, et al. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2α analogue. In: Samuelsson B, Ramwell PW, Paoletti R, et al, editors. Advances in prostaglandin, thromboxane, and leukotriene research. New York: Raven Press, Ltd, 1995: 513–8

    Google Scholar 

  67. Hedner J, Svedmyr N, Lunde H, et al. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Surv Ophthalmol 1997; 41Suppl. 2: S111–5

    Article  PubMed  Google Scholar 

  68. Alcon Ophthalmic. Azopt™ (brinzolamide ophthalmic suspension) 1%: prescribing information. Fort Worth (TX): Alcon Laboratories Inc., 1998

    Google Scholar 

  69. Merck & Co., Inc. Trusopt® (dorzolamide hydrochloride ophthalmic solution): prescribing information. West Point (PA): Merck& Co., Inc., 1998

    Google Scholar 

  70. Allergan Inc. Alphagan® (brimonidine tartrate ophthalmic solution) 0.2%: prescribing information. Irvine (CA): Allergan Inc., 1998

    Google Scholar 

  71. Derick RJ, Robin AL, Tielsch J, et al. Once-daily versus twice-daily levobunolol(0.5%)therapy: a crossover study. Ophthalmology 1992; 99(3): 424–9

    PubMed  CAS  Google Scholar 

  72. Novack GD. Ophthalmic beta-blockers since timolol. Surv Ophthalmol 1987; 31(5): 307–27

    Article  PubMed  CAS  Google Scholar 

  73. Stewart WC, Leland TM, Cate EA, et al. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure. J Glaucoma 1998; 7(6): 402–7

    PubMed  CAS  Google Scholar 

  74. Rakofsky SI, Melamed S, Cohen JS, et al. A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment. Ophthalmology 1989; 96(1): 8–11

    PubMed  CAS  Google Scholar 

  75. Nagasubramanian S, Sheth GP, Hitchings RA, et al. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension: comparison of dose regimens. Ophthalmology 1993; 100(9): 1305–11

    PubMed  CAS  Google Scholar 

  76. Lindén C, Alm A. Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity? Curr Eye Res 1998; 17(6): 567–72

    Article  PubMed  Google Scholar 

  77. Lindén C, Nuija E, Alm A. Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Ophthalmol 1997; 81(5): 370–2

    Article  PubMed  Google Scholar 

  78. Schlecht LP, Brubaker RF. The effects of withdrawal of timolol in chronically treated glaucoma patients. Ophthalmology 1988; 95(9): 1212–6

    PubMed  CAS  Google Scholar 

  79. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261(22): 3273–7

    Article  PubMed  CAS  Google Scholar 

  80. Kolker AE, Becker B. Epinephrine maculopathy. Arch Ophthalmol 1968; 79(5): 552–62

    Article  PubMed  CAS  Google Scholar 

  81. Michels RG, Maumenee AE. Cystoidmacular edema associated with topically applied epinephrine in aphakic eyes. Am J Ophthalmol 1975; 80 (3 Pt I): 379–88

    PubMed  CAS  Google Scholar 

  82. Thomas JV, Gragoudas ES, Blair NP, et al. Correlation of epinephrine use and macular edema in aphakic glaucomatous eyes. Arch Ophthalmol 1978; 96(4): 625–8

    Article  PubMed  CAS  Google Scholar 

  83. Diggory P, Heyworth P, Chau G, et al. Improved lung function tests on changing from topical timolol: non-selective betablockade impairs lung function tests in elderly patients. Eye 1993; 7 Pt 5: 661–3

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Nebraska Medical Centre, 600 South 42nd St, Omaha, Nebraska, 68198-5540, USA

    Carl B. Camras, Carol B. Toris & Richard R. Tamesis

Authors
  1. Carl B. Camras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol B. Toris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard R. Tamesis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carl B. Camras.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Camras, C.B., Toris, C.B. & Tamesis, R.R. Efficacy and Adverse Effects of Medications Used in the Treatment of Glaucoma. Drugs Aging 15, 377–388 (1999). https://doi.org/10.2165/00002512-199915050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199915050-00005

Keywords

Search

Navigation